NCT04798339View on ClinicalTrials.gov

Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 30, 2021

Primary Completion Date

May 26, 2025

Study Completion Date

July 31, 2026

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

Canakinumab Injection

Participants will be treated at 1 of 2 dose levels of Canakinumab, beginning at 150 mg and increasing to 300 mg or the Maximum Tolerated Dose

DRUG

Darbepoetin Alfa

Participants will receive Darbepoetin alfa subcutaneously at a dose of 300mg on days 1 and 15 of each cycle

Trial Locations (2)

30322

Emory-Winship Cancer Institute, Atlanta

33612

Moffitt Cancer Center, Tampa

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER